Paper23698643
Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
Scott SA and 10 others. Clin Pharmacol Ther, 2013. Cited by 722 papers, by iCite.
Cite this record
ConductScience Library. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Papers, record 23698643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/23698643
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Aryl Hydrocarbon Hydroxylases | Major topic |
| Platelet Aggregation Inhibitors | Major topic |
| Ticlopidine | Major topic |
| Clopidogrel | |
| Cytochrome P-450 CYP2C19 | |
| Genetic Testing | |
| Genetic Variation | |
| Genotype | |
| Humans | |
| Risk Assessment |
Source PubMed
Grants14
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| U01 HL105198 | NHLBI NIH HHS | United States | U01HL105198 | PubMed and NIH | NIH RePORTER |
| R24 GM061374 | NIGMS NIH HHS | United States | R24GM061374 | PubMed and NIH | NIH RePORTER |
| U01 GM074492 | NIGMS NIH HHS | United States | U01GM074492 | PubMed and NIH | NIH RePORTER |
| U19 HL065962 | NHLBI NIH HHS | United States | U01HL065962 | PubMed and NIH | NIH RePORTER |
| KL2 TR000069 | NCATS NIH HHS | United States | KL2TR000069 | PubMed and NIH | NIH RePORTER |
| U01HL105198 | NHLBI NIH HHS | United States | U01HL105198 | PubMed and NIH | NIH RePORTER |
| U01 HL065962 | NHLBI NIH HHS | United States | U01HL065962 | PubMed and NIH | NIH RePORTER |
| U01GM92666 | NIGMS NIH HHS | United States | U01GM092666 | PubMed and NIH | NIH RePORTER |
| KL2TR000069 | NCATS NIH HHS | United States | KL2TR000069 | PubMed and NIH | NIH RePORTER |
| U01 GM092666 | NIGMS NIH HHS | United States | U01GM092666 | PubMed and NIH | NIH RePORTER |
| U19HL065962-10 | NHLBI NIH HHS | United States | U19HL065962 | PubMed and NIH | NIH RePORTER |
| U01GM074492 | NIGMS NIH HHS | United States | U01GM074492 | PubMed and NIH | NIH RePORTER |
| U01HL65962 | NHLBI NIH HHS | United States | U01HL065962 | PubMed and NIH | NIH RePORTER |
| R24GM61374 | NIGMS NIH HHS | United States | R24GM061374 | PubMed and NIH | NIH RePORTER |
Trials2
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
| Trial | Title | The trial lists it as | Named in the paper's record | Source |
|---|---|---|---|---|
| NCT05091879 | Preemptive Pharmacogenomics Testing Among Geriatric Patients | Background | ClinicalTrials.gov | |
| NCT05763862 | Genotype Guided Antiplatelet Therapy In Ischemic Stroke | Background | ClinicalTrials.gov |
References40
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20062936 | Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. | Thromb Haemost | 2010 | https://conductscience.org/library/papers/20062936 | PubMed |
| 2 | 22809746 | 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. | J Am Coll Cardiol | 2012 | https://conductscience.org/library/papers/22809746 | PubMed |
| 3 | 19106083 | Genetic determinants of response to clopidogrel and cardiovascular events. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19106083 | PubMed |
| 4 | 19717846 | Ticagrelor versus clopidogrel in patients with acute coronary syndromes. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19717846 | PubMed |
| 5 | 16772608 | Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. | Blood | 2006 | https://conductscience.org/library/papers/16772608 | PubMed |
| 6 | 19108880 | Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. | Lancet | 2009 | https://conductscience.org/library/papers/19108880 | PubMed |
| 7 | 22513313 | Clopidogrel: a case for indication-specific pharmacogenetics. | Clin Pharmacol Ther | 2012 | https://conductscience.org/library/papers/22513313 | PubMed |
| 8 | 22028352 | Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. | JAMA | 2011 | https://conductscience.org/library/papers/22028352 | PubMed |
| 9 | 20801498 | Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. | Lancet | 2010 | https://conductscience.org/library/papers/20801498 | PubMed |
| 10 | 21270786 | CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. | Clin Pharmacol Ther | 2011 | https://conductscience.org/library/papers/21270786 | PubMed |
| 11 | 23809542 | The CYP2C19*17 variant is not independently associated with clopidogrel response. | J Thromb Haemost | 2013 | https://conductscience.org/library/papers/23809542 | PubMed |
| 12 | 21716271 | Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. | Clin Pharmacol Ther | 2011 | https://conductscience.org/library/papers/21716271 | PubMed |
| 13 | 19706858 | Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. | JAMA | 2009 | https://conductscience.org/library/papers/19706858 | PubMed |
| 14 | 19487603 | Can we override clopidogrel resistance? | Circulation | 2009 | https://conductscience.org/library/papers/19487603 | PubMed |
| 15 | 22027650 | PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19. | Pharmacogenet Genomics | 2012 | https://conductscience.org/library/papers/22027650 | PubMed |
| 16 | 20083681 | Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. | Circulation | 2010 | https://conductscience.org/library/papers/20083681 | PubMed |
| 17 | 19496924 | The CYP2C19*17 allele is associated with better platelet response to clopidogrel in patients admitted for non-ST acute coronary syndrome. | J Thromb Haemost | 2009 | https://conductscience.org/library/papers/19496924 | PubMed |
| 18 | 18055486 | Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. | Eur Heart J | 2008 | https://conductscience.org/library/papers/18055486 | PubMed |
| 19 | 19268736 | Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. | Am J Cardiol | 2009 | https://conductscience.org/library/papers/19268736 | PubMed |
| 20 | 19106084 | Cytochrome p-450 polymorphisms and response to clopidogrel. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19106084 | PubMed |
Cited by434
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 722 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42865374 | A prospective study evaluating clopidogrel resistance among patients with ischemic cerebrovascular events across different ethnic groups in Israel. | Front Stroke | 2026 | https://conductscience.org/library/papers/42865374 | PubMed |
| 42799099 | Implementation of preemptive pharmacogenetic testing: progress, puzzles and priorities from an implementation science perspective. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42799099 | PubMed |
| 42703526 | Association Between CYP450 Polymorphisms and Treatment Outcomes of Escitalopram and Venlafaxine in Patients with Post Stroke Depression. | Neuropsychiatr Dis Treat | 2026 | https://conductscience.org/library/papers/42703526 | PubMed |
| 42677320 | Repositioning candidate gene approaches in the post-GWAS era: a clinical perspective from psychiatric pharmacogenetics. | Front Genet | 2026 | https://conductscience.org/library/papers/42677320 | PubMed |
| 42583968 | Effectiveness of pharmacogenomics-guided dosing in improving treatment outcomes. | Indian J Pharmacol | 2026 | https://conductscience.org/library/papers/42583968 | PubMed |
| 42534206 | Long-Term Antithrombotic Therapy After Percutaneous Coronary Intervention: Secondary Prevention Beyond One Year. | Rev Cardiovasc Med | 2026 | https://conductscience.org/library/papers/42534206 | PubMed |
| 42195352 | The Role of Next-Generation Sequencing in Cardiovascular Disease: A New Era of Precision Cardiology. | Life (Basel) | 2026 | https://conductscience.org/library/papers/42195352 | PubMed |
| 42188087 | Is Aspirin Still Indispensable After PCI-Rethinking Dual Antiplatelet Therapy in Contemporary Practice. | J Cardiovasc Dev Dis | 2026 | https://conductscience.org/library/papers/42188087 | PubMed |
| 42115787 | Limited Visibility and Perception of the Clinical Relevance of Clopidogrel Pharmacogenetics in Cardiology Literature. | Clin Transl Sci | 2026 | https://conductscience.org/library/papers/42115787 | PubMed |
| 42051361 | Exploring Influencing Factors Including CYP2C19 Genotypes, and Developing a Machine Learning-Based Predictive Model for Clopidogrel Resistance in Chinese Patients with Ischemic Stroke. | Int J Gen Med | 2026 | https://conductscience.org/library/papers/42051361 | PubMed |
| 42042550 | The Environmental and Global Impact of Pharmacogenomics: Advancing Green Pharmacy Toward Sustainable and Inclusive Precision Medicine. | J Pers Med | 2026 | https://conductscience.org/library/papers/42042550 | PubMed |
| 41893359 | Pharmacometabolomics Detects Unreported Clopidogrel Metabolites in the Urine of Kidney and Liver Transplant Recipients. | Metabolites | 2026 | https://conductscience.org/library/papers/41893359 | PubMed |
| 41847134 | Prevalence of actionable pharmacogenomic variants in Brazilian patients with cancer. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/41847134 | PubMed |
| 41760043 | Antiplatelet dilemma: Clopidogrel or aspirin for long-term cardiovascular protection after dual antiplatelet therapy following PCI. | Medicine (Baltimore) | 2026 | https://conductscience.org/library/papers/41760043 | PubMed |
| 41749019 | CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute coronary syndromes (ACS) in 2026. | Cardiovasc Interv Ther | 2026 | https://conductscience.org/library/papers/41749019 | PubMed |
| 41728397 | Clinical Pharmacogenomic Variants Among the Saudi Population and Their Impact on Drug Response: A Review of Saudi-Based Evidence. | Cureus | 2026 | https://conductscience.org/library/papers/41728397 | PubMed |
| 41652975 | Importance of genetic ancestry in pharmacogenomics for precision medicine. | Pharmacogenomics | 2025 | https://conductscience.org/library/papers/41652975 | PubMed |
| 41617356 | Efficacy and safety of off-label low-dose compared with standard-dose antiplatelet agents in patients with coronary heart disease: a meta-analysis. | Open Heart | 2026 | https://conductscience.org/library/papers/41617356 | PubMed |
| 41471361 | Association Between CYP2C9 and CYP2C19 Genetic Polymorphisms and Antiseizure Medication-Induced Adverse Reactions Among Peruvian Patients with Epilepsy. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/41471361 | PubMed |
| 41338248 | CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI-PGx). | Br J Clin Pharmacol | 2026 | https://conductscience.org/library/papers/41338248 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| CYP2C19 | 1557 | PubTator's text mining | https://conductscience.org/library/genes/1557 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/23698643
GET https://conductscience.org/api/papers/v1/23698643/references?page=2